Thrombosis and Cancer - PowerPoint PPT Presentation

1 / 16
About This Presentation
Title:

Thrombosis and Cancer

Description:

Thrombosis and Cancer. Mario DICATO, Garry MAHON. Hematology-Oncology. Centre Hospitalier ... dicato.mario_at_chl.lu garry.mahon_at_cec.eu.int ... – PowerPoint PPT presentation

Number of Views:974
Avg rating:3.0/5.0
Slides: 17
Provided by: saisirvot
Category:

less

Transcript and Presenter's Notes

Title: Thrombosis and Cancer


1
Thrombosis and Cancer
  • Mario DICATO, Garry MAHON
  • Hematology-Oncology
  • Centre Hospitalier
  • L-1210 Luxembourg
  • dicato.mario_at_chl.lu garry.mahon_at_cec.eu.int

2
ESTIMATED PREVALENCE OF VENOUS THROMBOEMBOLISM
DURING THE COURSE OF COMMON TYPES OF CANCER (Ann.
Rev. Med. 1999)
3
CANCER TREATMENS AS RISK FACTORS FOR VTE IN
CANCER PATIENTS
4
  • TF, CP

VIIA Xa
TNF-IL-1
TF
VIIa
Tumor cells
monocytes endothelial cells
thrombin
Platelet aggregation
5
VENOUS THROMBOPHILIA
  • HEREDITARY Prevalence
  • AT III 0,2
  • Protein C , S 0,2
  • VArg 506 (Leiden) 3 - 8
  • Hyperhomocysteinemia ( arterial, folic acid),
    MTHFR 40 (35-60)
  • PT
    0-2
  • ? Plasminogen, Dysfibrinogenemia...

6
(No Transcript)
7
V Leiden
  • Prevalence
  • Heterozygotes (Caucasians) 5
  • Patient Cohorts DVT 20 - 60
  • DVT - Pregnancy 60
  • DVT - Oral Birth Control Meds 34
  • ! Multiple Genetic Deficits
  • Long term studies
  • heterozygotes ?
  • Ø arterial thrombosis

8
V LEIDEN, OESTROGENS AND DVT
  • VL OESTROGENS DVT (per 10.000 y)

  • - - 0,8
  • - 3
  • - 5,7
  • 28,5
  • HOMOZYGOSITY 100
  • (BMJ 1996, 313 1127)

9
ACQUIRED
  • ANTIPHOSPHOLIPID Ab
  • CANCER
  • PNH
  • MYELOPROLIFERATIVE SYNDROMES
  • NEPHROTIC SYNDROMES
  • CHEMOTHERAPY

10
V LEIDEN
  • Normal population controls 240
  • Heterozygotes 18
  • Homozygotes 0
  • Allele frequency 3,75
  • Essential thrombocytemia 41
  • Heterozygotes 3
  • Homozygotes 0
  • Allele frequency 3,65
  • M.
    Dicato et al. ASH 1998abstr.

11
ESSENTIAL THROMBOCYTHEMIA
  • n 41
  • V Leiden allele frequency 3,65
  • PT MTHFR (0 40)
  • n 30
  • 15 TED
  • 8 BLEEDING
  • 10 no hemostatic problem
  • (M.Dicato et al.
    ASH 1999, abstr.1119)

12
MUTATIONS V LEIDEN, MTHFR AND PT IN CANCER
PATIENTS WITH VENOUS THROMBO-EMBOLIC DISORDERS.
13
The Thrombophilic mutations V Leiden, PT and
MTHFR are in Hardy-Weinberg equilibrium
(ASH 2001, M.D. et al. abstr. 3985)
14
PATIENTS
  • Cancer VTE 54
  • Cancer - VTE 53

15
FREQUENCY OF MUTATIONS
16
CONCLUSION
  • In cancer patients with VTE, testing for
  • mutations is only useful if there is a
  • previous personal or family history
  • of VTE


(M. Dicato et al. ASH 2001, Abstr. 3984)
Write a Comment
User Comments (0)
About PowerShow.com